Zhong Ou, Wang Jinyuan, Tan Yongpeng, Lei Xiaocan, Tang Zhihan
Hengyang Medical School, University of South China, Hengyang, 421001, China.
Nutr Metab (Lond). 2022 Mar 18;19(1):20. doi: 10.1186/s12986-022-00653-9.
This meta-analysis was performed to investigate the effects of nicotinamide adenine dinucleotide (NAD+) precursor supplementation on glucose and lipid metabolism in human body.
PubMed, Embase, CENTRAL, Web of Science, Scopus databases were searched to collect clinical studies related to the supplement of NAD+ precursor from inception to February 2021. Then the retrieved documents were screened, the content of the documents that met the requirements was extracted. Meta-analysis and quality evaluation was performed detection were performed using RevMan5.4 software. Stata16 software was used to detect publication bias, Egger and Begg methods were mainly used. The main research terms of NAD+ precursors were Nicotinamide Riboside (NR), Nicotinamide Mononucleotide (NMN), Nicotinic Acid (NA), Nicotinamide (NAM). The changes in the levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and fasting blood glucose were mainly concerned.
A total of 40 articles were included in the meta-analysis, with a sample of 14,750 cases, including 7406 cases in the drug group and 7344 cases in the control group. The results of meta-analysis showed that: NAD+ precursor can significantly reduce TG level (SMD = - 0.35, 95% CI (- 0.52, - 0.18), P < 0.0001), and TC (SMD = - 0.33, 95% CI (- 0.51, - 0.14), P = 0.0005), and LDL (SMD = - 0.38, 95% CI (- 0.50, - 0.27), P < 0.00001), increase HDL level (SMD = 0.66, 95% CI (0.56, 0.76), P < 0.00001), and plasma glucose level in the patients (SMD = 0.27, 95% CI (0.12, 0.42), P = 0.0004). Subgroup analysis showed that supplementation of NA had the most significant effect on the levels of TG, TC, LDL, HDL and plasma glucose.
In this study, a meta-analysis based on currently published clinical trials with NAD+ precursors showed that supplementation with NAD+ precursors improved TG, TC, LDL, and HDL levels in humans, but resulted in hyperglycemia, compared with placebo or no treatment. Among them, NA has the most significant effect on improving lipid metabolism. In addition, although NR and NAM supplementation had no significant effect on improving human lipid metabolism, the role of NR and NAM could not be directly denied due to the few relevant studies at present. Based on subgroup analysis, we found that the supplement of NAD+ precursors seems to have little effect on healthy people, but it has a significant beneficial effect on patients with cardiovascular disease and dyslipidemia. Due to the limitation of the number and quality of included studies, the above conclusions need to be verified by more high-quality studies.
本荟萃分析旨在研究烟酰胺腺嘌呤二核苷酸(NAD+)前体补充剂对人体葡萄糖和脂质代谢的影响。
检索PubMed、Embase、CENTRAL、Web of Science、Scopus数据库,收集从数据库建立至2021年2月与NAD+前体补充剂相关的临床研究。然后对检索到的文献进行筛选,提取符合要求的文献内容。使用RevMan5.4软件进行荟萃分析和质量评估检测。使用Stata16软件检测发表偏倚,主要采用Egger法和Begg法。NAD+前体的主要研究术语为烟酰胺核糖(NR)、烟酰胺单核苷酸(NMN)、烟酸(NA)、烟酰胺(NAM)。主要关注甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)水平以及空腹血糖的变化。
本荟萃分析共纳入40篇文章,样本量为14750例,其中药物组7406例,对照组7344例。荟萃分析结果显示:NAD+前体可显著降低TG水平(标准化均数差[SMD]= -0.35,95%可信区间[CI](-0.52, -0.18),P < 0.0001)、TC水平(SMD = -0.33,95% CI (-0.51, -0.14),P = 0.0005)和LDL水平(SMD = -0.38,95% CI (-0.50, -0.27),P < 0.00001),提高HDL水平(SMD = 0.66,95% CI (0.56, 0.76),P < 0.00001),并使患者血浆葡萄糖水平升高(SMD = 0.27,95% CI (0.12, 0.42),P = 0.0004)。亚组分析表明,补充NA对TG、TC、LDL、HDL和血浆葡萄糖水平的影响最为显著。
在本研究中,基于目前已发表的关于NAD+前体的临床试验的荟萃分析表明,与安慰剂或不治疗相比,补充NAD+前体可改善人体的TG、TC、LDL和HDL水平,但会导致高血糖。其中,NA对改善脂质代谢的作用最为显著。此外,虽然补充NR和NAM对改善人体脂质代谢无显著作用,但由于目前相关研究较少,不能直接否定NR和NAM的作用。基于亚组分析,我们发现补充NAD+前体对健康人似乎没有什么影响,但对心血管疾病和血脂异常患者有显著的有益作用。由于纳入研究的数量和质量有限,上述结论需要更多高质量研究进行验证。